Health ❯ Healthcare ❯ Pharmaceuticals ❯ Weight Loss

GLP-1 Drugs

FDA Approves First Oral GLP-1 for Obesity as Novo’s Wegovy Pill Sets January U.S. Launch

The pill debuts with a $149 introductory cash price for the starter dose under a White House arrangement.

FDA Approves Wegovy Weight-Loss Pill as First Oral GLP-1 for Obesity

Lilly’s Daily Obesity Pill Sustains Weight Loss After Switch From Wegovy or Zepbound

WHO Endorses GLP‑1s for Obesity as Australia Adds Class‑Wide Mental Health Warning

Stopping GLP-1 Weight-Loss Drugs Before Pregnancy Linked to Higher Gestational Risks, Study Finds

U.S. Strikes Price-Cut Deals With Novo Nordisk and Eli Lilly for GLP‑1s, With Medicare Pilot in 2026

Lilly’s Oral GLP-1 Orforglipron Beats Farxiga and Placebo in Two Phase 3 Diabetes Trials

Sam’s Club Joins Costco in Offering $499 Wegovy and Ozempic

Half of Semaglutide Users Quit Within a Year as Higher Dose Trials Show Bigger Losses, More Side Effects

ESC Data Tie Wegovy and Mounjaro to Lower HFpEF Hospitalization and Death, With Novo Citing CV Edge for Wegovy

Lilly’s Orforglipron Pill Hits Phase 3 Goals, Clearing Path to Global Filings

Serena Williams Discloses 31-Pound Loss With GLP-1, Goes Public With Ro Partnership

Lilly’s Oral GLP-1 Pill Underperforms Wegovy in Late-Stage Trial

GLP-1 Weight-Loss Drugs Fail to Boost Fitness and Cause Significant Muscle Loss

UK Regulator Probes Pancreatitis Cases Linked to GLP-1 Weight-Loss Drugs

Novo Nordisk Launches Wegovy Weight-Loss Drug in India